- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03661047
OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer (OMICC)
OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is evaluating the effect of AMR101, as a chemopreventive agent to reduce risk of colorectal cancer in individuals with a history of colorectal cancer, colorectal mass or polyp(s).
AMR101 is made of marine omega-3 fatty acid, which is a family of natural substances found in the oil of certain fish, such as salmon and mackerel. Marine omega-3 fatty acid cannot be produced in sufficient amount by the human body and has to be obtained through diet or supplemented to maintain normal function in the body.
The U.S. Food and Drug Administration (FDA) has not approved AMR101 as a treatment for any disease. AMR101 is commercially available in the US as VASCEPA (icosapent ethyl).
The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits during which participants will complete a lifestyle questionnaire and a nutritional survey. A drug diary will be provided to be completed. Measurements will be taken, and blood and stool specimens will be collected. Tumor, colorectal mass, or polyp tissue will be collected for research purposes at the time of surgery or interventional endoscopy.
AMR101 administered daily, orally for up to 30 days and it is expected that 36 participants will take part in this study.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Participants must meet the following criteria on screening examination to be eligible to participate in the study:
Participants have histologically confirmed adenocarcinoma of the colon that is localized, with no evidence of distant metastasis (stage I, II, or III), and for which surgical resection of the primary tumor is being planned;
OR
Participants may have a colon biopsy that is suspicious for adenocarcinoma if clinical and/or endoscopic findings strongly support the presence of malignancy, and if surgical resection is being planned. NOTE: In the unlikely event that the final pathology of the surgical resection specimen is consistent with high-grade adenoma or dysplasia, the patient will not be considered ineligible and collected research samples will still be utilized.
OR
Participants have a diagnosis of a colorectal mass or polyp suspected to be a cancer or advanced adenoma at the most recent colonoscopy and are being referred to an advanced endoscopist to undergo interventional endoscopy within 30 days.
Age >= 18 years
This study will only include adult participants because colorectal carcinogenesis in children is more likely to be related to a cancer predisposition syndrome with distinct biological mechanisms compared with sporadic colorectal cancer in adults.
ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
Patients must be sufficiently healthy to undergo surgery/interventional endoscopy.
The effects of AMR101 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Subjects must be able and willing to follow study procedures and instructions.
Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.
Prior systemic or radiotherapy treatment for colorectal cancer.
Participants who are receiving any other investigational agents.
Concurrent use of other anti-cancer therapy, including chemotherapy agents, targeted agents, biological agents, immunotherapy, or investigational agents not otherwise specified in this protocol.
Inability or unwillingness to swallow pills.
History of malabsorption or uncontrolled vomiting or diarrhea, or any other disease that could interfere with absorption of oral medications.
History of allergic reactions attributed to fish or compounds of similar chemical or biologic composition to MO3PUFA.
Currently using or have used any fish oil supplement at any dose more than once per week within the last month.
Regularly consuming more than three servings of fish per week.
Known bleeding tendency/condition (e.g. von Willebrand disease)
Current use of anticoagulants or antiplatelet therapies, including aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs, including Ibuprofen [Advil, Motrin], Naproxen [Aleve, Anaprox DS, Naprosyn], and Celecoxib [Celebrex]), Heparin, Warfarin, Dalteparin sodium, Bivalirudin, Argatroban, Lepirudin, Heparin Sodium, Heparin/Dextrose, and an unwillingness or inability to discontinue anticoagulants.
Any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, may increase the risks associated with study participation or study treatment, limit compliance with study requirements, or interfere with the interpretation of study results.
Pregnant or breastfeeding.
The effects of AMR101 on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Similarly, lactating women are excluded from this study because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with AMR101. Consequently, breastfeeding should be discontinued if the mother is enrolled on the study.
Presence of synchronous (at the same time) malignancy for which the patient is currently receiving active treatment.
Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.
Participants with these infections are ineligible because they are at increased risk of significant complications in the perioperative period, and because fresh tissue from patients with these infections cannot be harvested for research purposes, per institutional policy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
Inclusion of Women and Minorities
Women and minorities will be eligible for this study without alteration in eligibility criteria. Enrollment of these underrepresented populations to this trial will be encouraged.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Omega-3 treatment
Daily 4-gram marine omega-3 polyunsaturated fatty acid (MO3PUFA), through treatment with AMR101 (VASCEPA, icosapent ethyl)
|
Oral administration, 4 grams per day
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Identical placebo
|
Oral administration, 4 grams per day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in the marine omega-3 polyunsaturated fatty acid (MO3PUFA) composition in colorectal tissues as a result of the AMR101 treatment for up to 30 days.
Time Frame: An average of 2 years after study completion
|
The effect of daily 4-gram AMR101 treatment on MO3PUFA composition in colorectal tissue will be measured through the extraction of fatty acid with gas chromatography-mass spectrometry from the biopsy tissue.
|
An average of 2 years after study completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in Tumor CD8+ T cells in the tumor tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
The influence of MO3PUFA treatment on the balance of Teff and Treg cells will be measured by the ratio of CD8+/Treg in the tumor microenvironment.
|
An average of 2 years after study completion
|
The change in gene expression profile of colorectal tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
RNA-seq analysis to profile gene expression in the mucosal tissue collected before and after AMR101 treatment will be performed to examine whether the AMR101 treatment reduces the gene expression of inflammatory cytokines, chemokines (e.g., TNFα, IL6 and CCL2), and immunosuppressive factors.
|
An average of 2 years after study completion
|
The change in protein levels of FOXP3 in the tumor tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
The changes in protein levels of T cell inhibitory markers will be measured before and after intervention.
|
An average of 2 years after study completion
|
The change in protein levels of IL10 in the tumor tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
The changes in protein levels of T cell inhibitory markers will be measured before and after intervention.
|
An average of 2 years after study completion
|
The change in protein levels of LAG-3 in the tumor tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
The changes in protein levels of T cell inhibitory markers will be measured before and after intervention.
|
An average of 2 years after study completion
|
The change in protein levels of CD49b in the tumor tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
The changes in protein levels of T cell inhibitory markers will be measured before and after intervention.
|
An average of 2 years after study completion
|
The change in protein levels of CTLA-4 in the tumor tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
The changes in protein levels of T cell immune checkpoints will be measured before and after intervention.
|
An average of 2 years after study completion
|
The change in protein levels of TIGIT in the tumor tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
The changes in protein levels of T cell immune checkpoints will be measured before and after intervention.
|
An average of 2 years after study completion
|
The change in protein levels of TIM-3 in the tumor tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
The changes in protein levels of T cell immune checkpoints will be measured before and after intervention.
|
An average of 2 years after study completion
|
The change in protein levels of PD-1 in the tumor tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
The changes in protein levels of T cell immune checkpoints will be measured before and after intervention.
|
An average of 2 years after study completion
|
The change in protein levels of PD-L1 in the tumor tissue between pre- and post- AMR101 treatment period.
Time Frame: An average of 2 years after study completion
|
The changes in protein levels of T cell immune checkpoints will be measured before and after intervention.
|
An average of 2 years after study completion
|
The change in the gut microbiome composition and function between pre- and post- AMR101 treatment period
Time Frame: An average of 2 years after study completion
|
Metagenomic and metatranscriptomic sequencing of microbial DNA and RNA on pre- and post-treatment stool samples will be performed to examine the biomolecular mechanisms by which gut microbial activity may be altered or respond to AMR101 treatment
|
An average of 2 years after study completion
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Hang D, Kvaerner AS, Ma W, Hu Y, Tabung FK, Nan H, Hu Z, Shen H, Mucci LA, Chan AT, Giovannucci EL, Song M. Coffee consumption and plasma biomarkers of metabolic and inflammatory pathways in US health professionals. Am J Clin Nutr. 2019 Mar 1;109(3):635-647. doi: 10.1093/ajcn/nqy295.
- Kvaerner AS, Hang D, Giovannucci EL, Willett WC, Chan AT, Song M. Trajectories of body fatness from age 5 to 60 y and plasma biomarker concentrations of the insulin-insulin-like growth factor system. Am J Clin Nutr. 2018 Aug 1;108(2):388-397. doi: 10.1093/ajcn/nqy103.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Platelet Aggregation Inhibitors
- Lipid Regulating Agents
- Eicosapentaenoic acid ethyl ester
Other Study ID Numbers
- 18-097
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Cancer
-
National Cancer Institute (NCI)NSABP Foundation IncCompletedColon Adenocarcinoma | Stage IIIA Colon Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage IIIC Colon Cancer AJCC v7 | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7United States
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation MedicineRecruitingStage II Colon Cancer | Stage III Colon Cancer | HER2-positive Colon Cancer | RAS Wild-type Colon CancerItaly
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedFatigue | Depressive Symptoms | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Psychosocial Effects of Cancer and Its Treatment | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingStage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8United States
-
Hospital da Senhora da OliveiraCompletedColon Cancer | Colon Adenoma | Colon Polyp | Colon Rectal CancerPortugal
-
National Cancer Institute (NCI)CompletedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
Howard S. Hochster, MDRecruitingStage IV Colon Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVC Colon Cancer AJCC v8 | Metastatic Colon CarcinomaUnited States
-
NorgineXolomon Tree S.L.CompletedColon Cancer | Colon Disease | Colon CleansingSpain, Portugal
Clinical Trials on AMR101 (VASCEPA, icosapent ethyl)
-
University of PennsylvaniaAmarin Pharma Inc.CompletedDyslipidemias | Lipid Disorder | Triglycerides HighUnited States
-
Amarin Pharma Inc.Completed
-
Amarin Pharma Inc.CompletedHypertriglyceridemiaUnited States, Netherlands, Russian Federation, Ukraine, Denmark, Finland, Germany, India, Italy, Mexico, South Africa
-
Amarin Pharma Inc.CompletedCardiovascular DiseasesUnited States, Australia, Canada, India, Netherlands, New Zealand, Poland, Romania, Russian Federation, South Africa, Ukraine
-
Canadian Medical and Surgical Knowledge Translation...Unity Health Toronto; Western University, Canada; HLS Therapeutics, IncCompletedCardiovascular Diseases | Diabetes Mellitus, Type 2 | Cardiovascular Risk Factor | Triglycerides HighCanada
-
Kaiser PermanenteAmarin CorporationTerminatedCardiovascular Diseases | Covid19 | Atherosclerosis | Upper Respiratory Tract InfectionsUnited States
-
Massachusetts General HospitalNational Institutes of Health (NIH)CompletedColorectal Cancer | Colorectal Adenoma | Gastrointestinal Microbiome | Endoscopic Surgery | Eicosapentaenoic AcidUnited States
-
Lundquist Institute for Biomedical Innovation at...Intermountain Research and Medical FoundationCompletedHypertriglyceridemiaUnited States
-
Matinas BioPharma Nanotechnologies, Inc.MB Clinical Research and Consulting LLC; Matinas Biopharma, IncCompletedHypertriglyceridemiaUnited States
-
Brigham and Women's HospitalTerminatedCoronary Artery Disease | Type 2 DiabetesUnited States